Relay Therapeutics (RLAY) CFO Thomas Catinazzo Sells 17,717 Shares

What Happened
Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics (RLAY), sold 17,717 shares in an open-market transaction on September 8, 2026. The sale generated approximately $335,560 using a weighted-average price of $18.94 per share. The trades were executed under a Rule 10b5-1 trading plan adopted October 30, 2025, indicating the sales were pre-arranged.

Key Details

• Transaction date: 2026-09-08; Form 4 filed: 2026-09-09.
• Shares sold: 17,717; weighted-average sale price: $18.94; total proceeds: ~$335,560.
• Price range: executed in multiple trades at $18.34 to $19.25 (weighted average reported). Reporting person offered to provide per-price breakdown on request.
• Footnotes: F1 = sale under a 10b5-1 plan (adopted 10/30/2025); F2 = multiple trade prices with weighted average; F3 = reported holdings include 6,538 shares underlying restricted stock units.
• Shares owned after transaction: the filing notes holdings include 6,538 RSU-based shares; the total post-sale share count is as reported on the Form 4.

Context
This was a sale (often considered a routine liquidity event) made under a pre-established 10b5-1 plan, which typically limits interpretation of the transaction as a near-term signal about the company’s prospects. No options exercises, gifts, or other derivative transactions were reported in this filing.